Skip to main content
. 2020 Jan 10;14(2):309–328. doi: 10.1002/1878-0261.12622

Figure 4.

Figure 4

DANCR critically controlled inflammation and targeted SOCS3 expression through EZH2‐mediated epigenetic regulation. ELISA assay showed that shDANCR potently reduced the secretions of IL‐6 (A) and TGF‐β (B) into the conditioned medium of indicated breast cancer cells. qRT‐PCR revealed reduced expressions of IL‐6 (C) and TGF‐β (D) in shDANCR cells. (E,F) Western blot showed that shDANCR markedly inhibited the activations of p65 and STAT3, but increased the expression of SOCS3 in malignant breast cancer cells. (G,H) Western blot on EZH2, H3K27me3, H3, and Hsp60 revealed specific reductions of H3K27me3 in shDANCR or GSK‐126‐treated cells. ChIP assay showed that the binding of EZH2 (I) and H3K27me3 (J) to the promoter of SOCS3 was significantly reduced in shDANCR or GSK‐126‐treated cells. (K) RNA immunoprecipitation assay revealed the specific interaction between DANCR and EZH2 in malignant breast cancer cells. IgG was used as the negative control. n = 3, data are shown as mean ± SD. Student’s t‐test (A–F) and one‐way ANOVA (G–K) were used to determine statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001.